4.2 Article

Toward Practical Integration of Omic and Imaging Data in Co-Clinical Trials

期刊

TOMOGRAPHY
卷 9, 期 2, 页码 810-828

出版社

MDPI
DOI: 10.3390/tomography9020066

关键词

magnetic resonance imaging (MRI); multi-omics; breast cancer; cancer informatics; cancer modeling; radiomics

向作者/读者索取更多资源

Co-clinical trials involve evaluating therapeutics in both patients and patient-derived xenografts (PDX) to determine how well PDX responses match patient responses, in order to inform pre-clinical and clinical trials. The challenge lies in managing and analyzing the vast amount of data generated across different scales and species. To overcome this challenge, a web-based tool called MIRACCL is being developed to correlate MRI-based changes in tumor characteristics with mRNA expression data in a co-clinical trial setting.
Co-clinical trials are the concurrent or sequential evaluation of therapeutics in both patients clinically and patient-derived xenografts (PDX) pre-clinically, in a manner designed to match the pharmacokinetics and pharmacodynamics of the agent(s) used. The primary goal is to determine the degree to which PDX cohort responses recapitulate patient cohort responses at the phenotypic and molecular levels, such that pre-clinical and clinical trials can inform one another. A major issue is how to manage, integrate, and analyze the abundance of data generated across both spatial and temporal scales, as well as across species. To address this issue, we are developing MIRACCL (molecular and imaging response analysis of co-clinical trials), a web-based analytical tool. For prototyping, we simulated data for a co-clinical trial in triple-negative breast cancer (TNBC) by pairing pre- (T0) and on-treatment (T1) magnetic resonance imaging (MRI) from the I-SPY2 trial, as well as PDX-based T0 and T1 MRI. Baseline (T0) and on-treatment (T1) RNA expression data were also simulated for TNBC and PDX. Image features derived from both datasets were cross-referenced to omic data to evaluate MIRACCL functionality for correlating and displaying MRI-based changes in tumor size, vascularity, and cellularity with changes in mRNA expression as a function of treatment.

作者

我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。

评论

主要评分

4.2
评分不足

次要评分

新颖性
-
重要性
-
科学严谨性
-
评价这篇论文

推荐

暂无数据
暂无数据